David Rescott

Q: What is David Rescott's success rate?

David Rescott currently has a success rate of 94.85225505443236.

Q: What is the average return of David Rescott's calls?

Their stock ratings have generated an average return of 9.664853466978634.

Baird | Healthcare

David Rescott is an analyst from Baird specializing in the Healthcare sector. Ranked #1495 out of 4749 analysts, they have issued 22 stock ratings with a success rate of 94.85% and an average return of 9.66%.

David Rescott has a well-established track record, with 22 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 94.85% and an average return of 9.66%, underscoring their expertise and ability to identify winning opportunities for investors.

#1495

Out of 4749

Total Ratings

+94.85%

Success Rate

+9.66%

Average Return

Recent Ratings Analysis

HTFL

Buy

Jul 31, 2026

Target

$34.00

Current

$25.83

Performance

—

David Rescott rated HTFL as Outperform on Jul 31, 2026, setting a price target of 34. Shares have remained stable near 25.83, leaving the 34 target still in play.

ISRG

Buy

Jul 17, 2026

Target

$500.00

Current

$352.97

Performance

2.19%

On Jul 17, 2026, ISRG was given a Outperform rating by David Rescott, with a target price of 500. The stock traded sideways with a 2.19% move, keeping the bullish thesis unresolved.

ABT

Buy

Jul 01, 2026

Target

$121.00

Current

$105.63

Performance

14.59%

ABT received a Outperform rating from David Rescott on Jul 01, 2026, aiming for 121. Momentum has favored the Buy call, with shares climbing from 105.625 to 105.625, rewarding those who trusted the recommendation.

MDT

Hold

Jun 04, 2026

Target

$85.00

Current

$85.71

Performance

4.61%

On Jun 04, 2026, David Rescott published a Neutral outlook on MDT, with a target of 85. Sideways action left the Hold view intact, with no major move since 85.71.

BSX

Buy

May 19, 2026

Target

$75.00

Current

$46.00

Performance

-19.03%

David Rescott on May 19, 2026 assigned BSX a Outperform rating, with a price target of 75. The call has struggled to gain traction, with shares losing 19.03%.

LIVN

Buy

May 07, 2026

Target

$76.00

Current

$81.05

Performance

14.27%

On May 07, 2026, David Rescott reaffirmed LIVN with a Outperform rating, targeting 76. The recommendation was supported by strong follow-through as the stock rose from 81.05 to 81.05.

EW

Hold

Apr 24, 2026

Target

$87.00

Current

$86.92

Performance

—

EW was rated Neutral by David Rescott on Apr 24, 2026, with a price objective of 87. Flat performance suggests the Hold view was reasonable.

PRCT

Hold

Mar 06, 2026

Target

$30.00

Current

$18.00

Performance

-25.68%

On Mar 06, 2026, David Rescott initiated coverage on PRCT with a Neutral rating and target of 30. The rating matched the stock’s inability to hold above 18.

PEN

Hold

Jan 16, 2026

Target

$374.00

Current

$319.83

Performance

-8.82%

David Rescott issued a Neutral recommendation for PEN on Jan 16, 2026, price target set at 374. Market action validated the conservative Hold outlook with shares at 319.83.

SIBN

Buy

Dec 18, 2025

Target

$23.00

Current

$17.99

Performance

—

On Dec 18, 2025, SIBN was evaluated by David Rescott, who gave a Buy rating and target of 23. So far, the Buy call awaits clearer momentum, with shares flat at 17.99.

HAE

Buy

Dec 15, 2025

Target

$99.00

Current

$84.82

Performance

5.50%

David Rescott rated HAE as Outperform on Dec 15, 2025, setting a price target of 99. The call has proven timely, with shares rising 5.50% toward the price target of 99.

NARI

Hold

Jan 07, 2025

Target

$80.00

Current

$79.97

Performance

0.65%

On Jan 07, 2025, NARI was given a Neutral rating by David Rescott, with a target price of 80. Market indecision, reflected in sideways trading near 79.97, supported the cautious call.

IRTC

Buy

Jul 16, 2024

Target

$134.00

Current

$119.08

Performance

13.45%

IRTC received a Buy rating from David Rescott on Jul 16, 2024, aiming for 134. Momentum has favored the Buy call, with shares climbing from 119.08 to 119.08, rewarding those who trusted the recommendation.

MMSI

Buy

Jun 28, 2024

Target

$96.00

Current

$83.35

Performance

-3.03%

On Jun 28, 2024, David Rescott published a Outperform outlook on MMSI, with a target of 96. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 83.35.

Frequency Asked Questions

Who is David Rescott?

David Rescott is an analyst from Baird specializing in the Healthcare sector.

What is David Rescott's success rate?

David Rescott currently has a success rate of +94.85%.

How many ratings has David Rescott issued?

David Rescott has issued 22 stock ratings so far.

What is the average return of David Rescott's calls?

Their stock ratings have generated an average return of +9.66%.

What is David Rescott's ranking?

David Rescott is ranked #1495 out of 4749 analysts.

What types of ratings does David Rescott give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Rescott?

You can follow David Rescott by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Rescott?

Their latest rating was a Buy on HTFL issued on 2026-07-31.